NEXGEL prelim Q4 rev ~$3M, FY2024 ~$8.6M (+100% YoY); guides FY2025 >$13M, cash flow positive

NEXGEL, INC.

2024-FY EPS reported -$0.50 revenue$8,688,000

Preliminary Q4 2024 revenue ~$3.0M; full year ~$8.6M, representing >100% YoY growth for third consecutive year.
2025 guidance: at least $13M revenue and positive cash flow from operations during the year.
Silly George run rate grew from $2M to >$5M post-acquisition (May 2024); new beauty under-eye patch planned.
Contract manufacturing added two large international customers; one began Q4 revenue, other expected Q1 2025.
Medagel to launch SilverSeal wound kit and burn pads; Kenkoderm to expand into new indication Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.